Radiation Oncology Journal

  • 제37권3호
  • /
  • Pages.207-214
  • /
  • 2019
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지
DOI QR코드

DOI QR Code

Prognostic factors in hepatocellular carcinoma patients with bone metastases

  • Kim, Sungmin (Department of Radiation Oncology, Dong-A University Hospital, Dong-A University College of Medicine) ;
  • Choi, Youngmin (Department of Radiation Oncology, Dong-A University Hospital, Dong-A University College of Medicine) ;
  • Kwak, Dong-Won (Department of Radiation Oncology, Dong-A University Hospital, Dong-A University College of Medicine) ;
  • Lee, Hyung Sik (Department of Radiation Oncology, Dong-A University Hospital, Dong-A University College of Medicine) ;
  • Hur, Won-Joo (Department of Radiation Oncology, Dong-A University Hospital, Dong-A University College of Medicine) ;
  • Baek, Yang Hyun (Department of Internal Medicine, Dong-A University Hospital, Dong-A University College of Medicine) ;
  • Lee, Sung Wook (Department of Internal Medicine, Dong-A University Hospital, Dong-A University College of Medicine)
  • 투고 : 2019.02.28
  • 심사 : 2019.07.22
  • 발행 : 2019.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: To identify the prognostic factors that could influence survival and to compare prognoses of the patients with the number of the risk factors that might assist in the adequate management of hepatocellular carcinoma (HCC) patients with bone metastases that showed a heterogeneous range of survival. Materials and Methods: A total of 41 patients, treated with radiotherapy (RT) for bone metastases from HCC from 2014 to 2017, were enrolled retrospectively. Survival was determined by the Kaplan-Meier method from the start of the RT for metastatic bone lesions. Pre-RT clinical features were evaluated and their influences on survival were analyzed. The significant factors were considered to compare survivals according to the number of prognostic factors. Results: Median follow-up was 6.0 months (range, 0.5 to 47.0 months). The median overall survival was 6.5 months, and the 1-year and 2-year survival rates were 35.5% and 13.5%, respectively. Multivariate analysis revealed that the Child-Pugh class A group, alpha-fetoprotein increased more than 30 ng/mL, and HCC size of more than 5 cm were associated with worse overall survival. The median survivals in HCC with none, 1, 2, and 3 of the aforementioned risk factors were 19.5, 9.0, 2.5, and 1.0 months, respectively (p < 0.05). Conclusion: Our results show that the overall survivals were significantly different according to the number of the risk factors among HCC patients with bone metastases who showed various lengths of survival.

키워드

참고문헌

  1. Kim BH, Park JW. Epidemiology of liver cancer in South Korea. Clin Mol Hepatol 2018;24:1-9. https://doi.org/10.3350/cmh.2017.0112
  2. Kim BH, Lim YS, Kim EY, et al. Temporal improvement in survival of patients with hepatocellular carcinoma in a hepatitis B virus-endemic population. J Gastroenterol Hepatol 2018;33:475-83. https://doi.org/10.1111/jgh.13848
  3. Lee YT, Geer DA. Primary liver cancer: pattern of metastasis. J Surg Oncol 1987;36:26-31. https://doi.org/10.1002/jso.2930360107
  4. Toyoda H, Kumada T, Kiriyama S, et al. Changes in the characteristics and survival rate of hepatocellular carcinoma from 1976 to 2000: analysis of 1365 patients in a single institution in Japan. Cancer 2004;100:2415-21. https://doi.org/10.1002/cncr.20289
  5. Ho CL, Chen S, Yeung DW, Cheng TK. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 2007;48:902-9. https://doi.org/10.2967/jnumed.106.036673
  6. Harding JJ, Abu-Zeinah G, Chou JF, et al. Frequency, morbidity, and mortality of bone metastases in advanced hepatocellular carcinoma. J Natl Compr Canc Netw 2018;16:50-8. https://doi.org/10.6004/jnccn.2017.7024
  7. Uchino K, Tateishi R, Shiina S, et al. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer 2011;117:4475-83. https://doi.org/10.1002/cncr.25960
  8. Katyal S, Oliver JH 3rd, Peterson MS, Ferris JV, Carr BS, Baron RL. Extrahepatic metastases of hepatocellular carcinoma. Radiology 2000;216:698-703. https://doi.org/10.1148/radiology.216.3.r00se24698
  9. Natsuizaka M, Omura T, Akaike T, et al. Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol 2005;20:1781-7. https://doi.org/10.1111/j.1440-1746.2005.03919.x
  10. Fukutomi M, Yokota M, Chuman H, et al. Increased incidence of bone metastases in hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2001;13:1083-8. https://doi.org/10.1097/00042737-200109000-00015
  11. Lu Y, Hu JG, Lin XJ, Li XG. Bone metastases from hepatocellular carcinoma: clinical features and prognostic factors. Hepatobiliary Pancreat Dis Int 2017;16:499-505. https://doi.org/10.1016/S1499-3872(16)60173-X
  12. Jung IH, Yoon SM, Kwak J, et al. High-dose radiotherapy is associated with better local control of bone metastasis from hepatocellular carcinoma. Oncotarget 2017;8:15182-92. https://doi.org/10.18632/oncotarget.14858
  13. Chang SS, Luo JC, Chao Y, et al. The clinical features and prognostic factors of hepatocellular carcinoma patients with spinal metastasis. Eur J Gastroenterol Hepatol 2001;13:1341-5. https://doi.org/10.1097/00042737-200111000-00013
  14. Chang UK, Kim MS, Han CJ, Lee DH. Clinical result of stereotactic radiosurgery for spinal metastasis from hepatocellular carcinoma: comparison with conventional radiation therapy. J Neurooncol 2014;119:141-8. https://doi.org/10.1007/s11060-014-1463-9
  15. He J, Zeng ZC, Tang ZY, et al. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy. Cancer 2009;115:2710-20. https://doi.org/10.1002/cncr.24300
  16. Saarto T, Janes R, Tenhunen M, Kouri M. Palliative radiotherapy in the treatment of skeletal metastases. Eur J Pain 2002;6:323-30. https://doi.org/10.1016/S1090-3801(02)00028-9
  17. Lee MH, Lee SH, Kim ES, Eoh W, Chung SS, Lee CS. Survivalrelated factors of spinal metastasis with hepatocellular carcinoma in current surgical treatment modalities: a single institute experience. J Korean Neurosurg Soc 2015;58:448-53. https://doi.org/10.3340/jkns.2015.58.5.448
  18. Rim CH, Choi C, Choi J, Seong J. Establishment of a diseasespecific graded prognostic assessment for hepatocellular carcinoma patients with spinal metastasis. Gut Liver 2017;11:535-42. https://doi.org/10.5009/gnl16486
  19. Choi C, Seong J. Predictive factors of palliative radiotherapy response and survival in patients with spinal metastases from hepatocellular carcinoma. Gut Liver 2015;9:94-102. https://doi.org/10.5009/gnl14009
  20. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47. https://doi.org/10.1016/j.ejca.2008.10.026
  21. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60. https://doi.org/10.1055/s-0030-1247132
  22. Ryu S, Jin JY, Jin R, et al. Partial volume tolerance of the spinal cord and complications of single-dose radiosurgery. Cancer 2007;109:628-36. https://doi.org/10.1002/cncr.22442
  23. Ryu S, Yoon H, Stessin A, Gutman F, Rosiello A, Davis R. Contemporary treatment with radiosurgery for spine metastasis and spinal cord compression in 2015. Radiat Oncol J 2015;33:1-11. https://doi.org/10.3857/roj.2015.33.1.1
  24. Chow E, Hoskin P, Mitera G, et al. Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Int J Radiat Oncol Biol Phys 2012;82:1730-7. https://doi.org/10.1016/j.ijrobp.2011.02.008
  25. Statistics Korea. Annual report of cancer statistics in 2016. Daejeon: Statistics Korea; 2019.
  26. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol 2000;31:302-8. https://doi.org/10.1097/00004836-200012000-00007
  27. Bai DS, Zhang C, Chen P, Jin SJ, Jiang GQ. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep 2017;7:12870. https://doi.org/10.1038/s41598-017-12834-1